STOCK TITAN
  1. Home
  2. News
  3. SNSE

Sensei Biotherapeutics Inc - SNSE STOCK NEWS

Welcome to our dedicated news page for Sensei Biotherapeutics (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sensei Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sensei Biotherapeutics's position in the market.

News
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
Rhea-AI Summary
Sensei Biotherapeutics, Inc. (SNSE) will participate in Canaccord Genuity's Horizons in Oncology Virtual Conference to discuss KRAS and VISTA targeting in cancer therapy. Dr. Shiraj Sen will represent the company and share insights on the Phase 1/2 clinical trial for SNS-101.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.28%
Tags
conferences
-
News
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment
Rhea-AI Summary
Sensei Biotherapeutics, Inc. (SNSE) announces the publication of a research paper in Nature Communications detailing the development of SNS-101, a pH-sensitive monoclonal antibody targeting VISTA to suppress T-cell activation in cancer patients. The paper highlights the unique mechanism of SNS-101 in mitigating CRS risk and maintaining a favorable safety profile, potentially revolutionizing VISTA-directed immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
none
-
News
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
Rhea-AI Summary
Sensei Biotherapeutics, Inc. (SNSE) will participate in the 3rd Annual VISTA Symposium to discuss Anti-VISTA Immunotherapies in Clinical Development. The symposium will focus on the role of VISTA in cancer immunotherapy and ongoing clinical development of anti-VISTA therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.43%
Tags
conferences
News
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
Rhea-AI Summary
Sensei Biotherapeutics, Inc. (SNSE) announces the presentation of preclinical data on its immuno-oncology programs at scientific conferences. The company will showcase its innovative therapies targeting immune checkpoint pathways to enhance cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
conferences clinical trial
-
News
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
Sensei Biotherapeutics, Inc. (SNSE) reports positive clinical data on SNS-101, showing a potentially best-in-class safety profile and PK, with topline efficacy data expected in Q2 2024. The company plans an end-of-Phase 1 meeting with the FDA in Q4 2024. Sensei's strong balance sheet extends cash runway into Q4 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
earnings
-
News
Sensei Biotherapeutics to Present at Upcoming Conferences
Rhea-AI Summary
Sensei Biotherapeutics, Inc. (SNSE) will be presenting at Oppenheimer's 34th Annual Healthcare Life Sciences Conference and the 10th Annual Immuno-Oncology 360 Conference in February 2024. The company's management will present virtually at the Oppenheimer conference and in person at the IO360 conference in Brooklyn, NY. A webcast of the Oppenheimer presentation will be available on the Sensei website, with a replay available for 90 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
conferences
News
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
Rhea-AI Summary
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) completes SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities, expands patient cohort in specific tumor types, and expects multiple clinical milestones in 2024. The company maintains a strong balance sheet with cash runway extended into the fourth quarter of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none
-
News
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) reported favorable clinical data on SNS-101, showing a best-in-class safety and pharmacokinetic profile. The company's strong balance sheet with cash runway into the second half of 2025 was also highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
earnings
-
News
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
Rhea-AI Summary
Sensei Biotherapeutics reports positive clinical data for SNS-101, a VISTA-blocking antibody, in its Phase 1/2 clinical trial. The data show a well-tolerated safety profile, potentially best-in-class pharmacokinetics, and encouraging cytokine release profile. The antibody has the potential to overcome challenges faced by first generation VISTA blockers. Sensei expects to report more data in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
Rhea-AI Summary
Sensei Biotherapeutics, Inc. has appointed Stephanie Krebs as Chief Business Officer. Ms. Krebs brings extensive experience in business development and corporate partnerships in the biotech industry. She will be responsible for driving strategic alliances and advancing the company's clinical trials and pipeline expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.33%
Tags
management
Stock SNSE logo
Sensei Biotherapeutics Inc

Nasdaq:SNSE

SNSE Rankings

#5055 Ranked by Market Cap
#4942 Ranked by Stock Gains
N/A Ranked by Dividends

SNSE Stock Data

26.32M
16.41M
34.65%
10.55%
0.62%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Rockville

About SNSE

sensei biotherapeutics is an innovator in the field of next-generation cancer immunotherapies. sensei has pioneered a proprietary immuno-oncology technology platform, called spirit, to aid the immune system in the detection and elimination of cancer. the presence of subtle differences in antigen expression between cancer and normal is key to this process the spirit platform overcomes disabled immune recognition caused by cancer. the immune system has evolved to protect its host from foreign pathogens, effectively distinguishing healthy ‘self’ tissues from ‘non-self’. cancer is a unique challenge to the immune system. it arises from ‘self’ making immune recognition challenging, yet it is known to be altered. immune recognition of the subtle differences between ‘self’ and ‘non-self’ is key to effective cancer immunotherapy. headquartered in gaithersburg, md, sensei has built a unique and proprietary approach in-house and in collaboration with key academic collaborators at brown universit